TIVC · Valion Bio, Inc.

Tivic Health Systems reported a GAAP net loss of -$8.9 million for fiscal 2025, representing a 57.0% widening from the prior year's -$5.7 million. This expansion stems from the Company's deliberate investments in product innovation and development as it pivots toward biopharma opportunities, including the December 2025 launch of Velocity Bioworks, Inc., a wholly owned contract development and manufacturing organization (CDMO) subsidiary. By acquiring assets to establish this unit, Tivic aims to secure greater control over manufacturing processes, reducing reliance on external partners while navigating the costs of standing up new operations. Concurrently, the Company has intentionally maintained a lean structure, decreasing headcount to curb operating expenses and preserve resources for core priorities.

Operationally, sales volume declined from the prior year, attributed to reduced unit sales and lower advertising and marketing costs, as the Company shifts away from prior consumer-focused activities toward biopharma. A decrease in orders during the period could pressure future revenues, highlighting execution risks in this formative stage. Management notes that potential tariffs on imports from China, Canada, or other countries could elevate costs and compress gross margins, adding external headwinds to the cost structure.

Looking ahead, ongoing losses and cash burn signal substantial liquidity risks. The Company anticipates needing additional capital to sustain operations, fund research and development, clinical trials, and potential commercialization of product candidates pending regulatory approval. This going concern context emphasizes the high-stakes nature of the biopharma bet, where near-term financing will be critical to bridging to value inflection points.